Azian M, Hapizah M N, Khalid B A K, Khalid Y, Rosli A, Jamal R
UKM Medical Molecular Biology Institute, Department of Pathology, Kuala Lumpur, Malaysia.
Malays J Pathol. 2006 Jun;28(1):7-15.
Familial hypercholesterolaemia (FH) and Familial defective apolipoprotein B100 (FDB) are autosomal dominant inherited diseases of lipid metabolism caused by mutations in the low density lipoprotein (LDL) receptor and apolipoprotein B 100 genes. FH is clinically characterised by elevated concentrations of total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C), presence of xanthomata and premature atherosclerosis. Both conditions are associated with coronary artery disease but may be clinically indistinguishable. Seventy-two (72) FH patients were diagnosed based on the Simon Broome's criteria. Mutational screening was performed by polymerase chain reaction (PCR)-denaturing gradient gel electrophoresis (DGGE). Positive mutations were subjected to DNA sequencing for confirmation of the mutation. We successfully amplified all exons in the LDL receptor and apo B100 genes. DGGE was performed in all exons of the LDL receptor (except for exons 4-3', 18 and promoter region) and apo B100 genes. We have identified four different mutations in the LDL receptor gene but no mutation was detected in the apo B 100 gene. The apo B100 gene mutation was not detected on DGGE screening as sequencing was not performed for negative cases on DGGE technique. To our knowledge, the C234S mutation (exon 5) is a novel mutation worldwide. The D69N mutation (exon 3) has been reported locally while the R385W (exon 9) and R716G (exon 15) mutations have not been reported locally. However, only 4 mutations have been identified among 14/72 patients (19.4%) in 39 FH families. Specificity (1-false positive) of this technique was 44.7% based on the fact that 42/76 (55.3%) samples with band shifts showed normal DNA sequencing results. A more sensitive method needs to be addressed in future studies in order to fully characterise the LDLR and apo B100 genes such as denaturing high performance liquid chromatography. In conclusion, we have developed the DNA analysis for FH patients using PCR-DGGE technique. DNA analysis plays an important role to characterise the type of mutations and forms an adjunct to clinical diagnosis.
家族性高胆固醇血症(FH)和家族性载脂蛋白B100缺陷症(FDB)是由低密度脂蛋白(LDL)受体和载脂蛋白B100基因突变引起的脂质代谢常染色体显性遗传病。FH的临床特征为总胆固醇(TC)和低密度脂蛋白胆固醇(LDL-C)浓度升高、存在黄瘤和早发性动脉粥样硬化。这两种情况均与冠状动脉疾病相关,但在临床上可能难以区分。根据西蒙·布鲁姆标准诊断出72例FH患者。通过聚合酶链反应(PCR)-变性梯度凝胶电泳(DGGE)进行突变筛查。对阳性突变进行DNA测序以确认突变。我们成功扩增了LDL受体和载脂蛋白B100基因的所有外显子。对LDL受体(外显子4-3'、18和启动子区域除外)和载脂蛋白B100基因的所有外显子进行了DGGE分析。我们在LDL受体基因中鉴定出四种不同的突变,但在载脂蛋白B100基因中未检测到突变。由于未对DGGE技术检测为阴性的病例进行测序,因此在DGGE筛查中未检测到载脂蛋白B100基因突变。据我们所知,C234S突变(外显子5)是全球范围内的一种新突变。D69N突变(外显子3)在本地已有报道,而R385W(外显子9)和R716G(外显子15)突变在本地尚未见报道。然而,在39个FH家族的14/72例患者(19.4%)中仅鉴定出4种突变。基于42/76(55.3%)出现条带迁移的样本显示DNA测序结果正常这一事实,该技术的特异性(1-假阳性)为44.7%。未来的研究需要采用更敏感的方法,以便全面鉴定LDLR和载脂蛋白B100基因,如变性高效液相色谱法。总之,我们利用PCR-DGGE技术对FH患者开展了DNA分析。DNA分析在鉴定突变类型方面发挥着重要作用,并可作为临床诊断的辅助手段。